The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease

Abstract INTRODUCTION Anti‐amyloid therapies can slow Alzheimer's disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti‐amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression by 29% over individuals’ remaining lifetime (baseline mean age: 73.0); earlier treatment initiated 2 years earlier. RESULTS Treatment generated $104,885 (95% CI: $99,291, $110,479) in gross societal value over an individual's lifetime, including quality‐of‐life gains, reduced caregiving burden, and medical cost offsets driven by reduced nursing home use and Medicaid spending. Earlier treatment increased value 32%; this rose to 71% if treatment effects are also stronger (36% slowing) in earlier AD stages. Scenarios with 4‐year effect duration yielded $49,122 (treatment) and $56,385 (earlier treatment). DISCUSSION Timely treatment consistently increased long‐term societal value. The findings provide a benchmark against which treatment implementation costs can be weighed.